Shares of Thyrocare Technologies dipped 9.1 per cent to Rs 1,317on the BSE in Monday's intra-day after digital healthcare company Pharmeasy announced that it would buy a controlling stake in the diagnostic chain for Rs 4,546 crore.The Delhi-based company would buy 66.1 per cent stake in Thyrocare from promoter A Velumani and his affiliates at Rs 1,300 per share. Dr A Velumani, the founder of Thyrocare, will be separately acquiring a minority non-controlling stake, of less than 5 percent in API Holdings as part of a series of equity investments by existing and new investors of API, the statement added.The proposed deal shocked investors as the deal price was 11% lower than the stock price of the firm.This would be the first ever acquisition of a listed company, by an Indian unicorn, the companies said in a joint statement. "It is the third big-ticket transaction involving an e-pharmacy company," they said.The stock price has surged over 176 percent in last 1 year.
Read more